

Clinical Group

17 June 2020

Global context

- Countries are at different stages of epidemic trajectory
- Huge differences in numbers of cases and pressure on health systems
- Some countries 'learning by doing'; others 'learning by watching'
- Beginning to switch from emergency phase to management phase of pandemic
- Moving from zero knowledge to information overload
- How to practise evidence-based medicine in a dynamic environment



Clinical strategies

Preparedness

- Building of ICU capacity, HCW training
- Suspension of routine procedures
- Challenges to healthcare delivery; capacity in private system, no ICU beds in public system.

Community-oriented approaches

- Proactive testing in vulnerable areas (e.g. slums)
- Virtual hospital telemedicine, self-testing
- Community quarantining; isolation of +ve patients

Patient pathways

- Diagnosis/admission protocols;
- Triage when ICU capacity exceeded

Patient management

- Risk stratification; personalising treatment
- Recognition of different phenotypes of patients; P-SILI should be managed differently from ARDS
- Developing algorithms to predict deterioration

Evidence generation/use

- COVID-19 local clinical guidelines/pathways
- Technical advisory groups, rapid evidence reviews
- Launch of clinical trials (e.g. SOLIDARITY), has worked well, even in hard-pressed settings.



Clinical care interventions

- Oxygen therapy (high-flow esp)/intubation
- Dexamethasone in ICU (ventilated patients); other steroids
- Prone positioning
- Treating cytokine storm (e.g. tocilizumab)
- Risk factor control comorbidities (diabetes etc.)
- Anticoagulation (when, which and how much?)
- Chloroquine, antivirals, remdesivir (compassionate use)
- Convalescent plasma (experience of haemorrhagic fevers)



Factors facilitating the formulation and adoption of clinical research findings into policy and guidelines?

- Learning from relevant previous experience (eg SARS)
- Local expert opinion, experience
- Local trials



What are the clinical knowledge or research gaps to sustain the management of COVID-19? (1 of 2)

- Anti-coagulation when, which agents, which dose, which duration ***
- Immunomodulators when, which agents, how to monitor **
- Distinguishing pneumonia vs pulmonary infarction; role of lung ultrasound **
- Appropriate use of remdesivir/antivirals in low-risk/early patients
- Ventilation vs high-flow oxygen/CPAP
- Timing of dexamethasone, other steroid use
- Minimising chronic complications (e.g. in lung)
- When to de-escalate isolation



What are the clinical knowledge or research gaps to sustain the management of COVID-19? (2 of 2)

- Home-based triaging to identify high-risk patients **
- Efficacy of convalescent plasma, IVIG
- Long-term protection offered by antibodies ***
- Hydroxychloroquine: preventive, therapeutic use
- BCG protection
- Genetic predisposition to poor outcomes (inc. children)
- Keeping HCW safe; IPC, PPE what works?
- Health services research how to integrate COVID-19 and other essential services



Providing an enabling environment to facilitate clinical care

- Mentorship to expand clinical capacity
- Managing information tsunami
- Virtual discussion sessions/webinars
- Development of innovative approaches eg virtual hospitals
- Mobilisation of private sector



Improving research collaboration among countries to address clinical evidence gaps

- Global networks with interest in COVID-19 research
- Expedited research approval processes
- Expedited funding calls
- Collaborations and international multicentre studies; protocol extension to new countries
- Help with regulatory approvals; accelerated assessment
- Innovative clinical trial design (e.g. adaptive)



Acknowledgements

Name	Country
Professor Rosalind Smyth CBE FMedSci	UK
Dr Juan Antonio Mazzei	Argentina
Dr Horacio López	Argentina
Acads. Patrícia Rocco	Brazil
Acads. Celso Ramos-Filho	Brazil
Professor Jacob John	India
Professor Anurag Agarwal	India
Professor Dr Adeeba Kamarulzaman	Malaysia
Dr Suresh Kumar	Malaysia
Dr Regina Berba	Philippines
Dr Marissa Alejandria	Philippines
Professor Michael Pepper	South Africa
Dr Arifa Parker	South Africa
Dr Arthur Kwizera	Uganda
Dr Rama Vancheeswaran	UK
Dr Merlin Willcox	UK
Dr Matthew Knight	UK
AMS Secretariat: Alex Hulme, Abigail Bloy and Fern Brookes	UK
Facilitator: Ian Jones	UK

